RxDoctor Payments Data

Trina Mattingly, APRN

Pediatrics · Irvine, KYNPI 1316993165

Payments from drug & device makers

$480in general payments, 2019–2025

Across 16 payments — averaging $30.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$150
  • Lilly USA, LLC$91
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$38
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$24
  • Abbott$23
  • Axsome Therapeutics, Inc.$21
  • plus $133 from 8 others

What the payments were for

  • Food & beverage$480100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$480 in reported general payments places this provider in the 60th percentile of 777 pediatrics providers in Kentucky.

See all pediatrics providers in Kentucky

Medicare billing

Part B allowed, 2024
$2,279
Medicare patients
18
Services billed
32

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter75$65,853
OzempicSemaglutide53$65,604
JardianceEmpagliflozin29$40,165
MounjaroTirzepatide36$37,344
LinzessLinaclotide43$36,413
FarxigaDapagliflozin Propanediol16$22,231
EliquisApixaban21$20,120
TrulicityDulaglutide14$15,136
Spiriva HandihalerTiotropium Bromide13$14,271
XareltoRivaroxaban18$13,671
Combivent RespimatIpratropium/Albuterol Sulfate22$11,315
Breo ElliptaFluticasone/Vilanterol18$11,282
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$7,323
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$2,812
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$2,451

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$18$65,60453 claims
Lilly USA, LLCMounjaro, Trulicity$91$52,48050 claims
AbbVieLinzess$150$36,41343 claims
AstraZenecaFarxiga$16$22,23116 claims
Johnson & JohnsonXarelto$15$13,67118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 777 pediatrics providers in Kentucky.

Other pediatrics in Irvine

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →